Founded in 1988, Guangzhou Baiyunshan Pharmaceutical Group is well-known in the industry for its Banlangen products, and is the largest monomer Chinese medicine manufacturer in South China

Guangzhou Baiyunshan Hutchison Whampoa Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Baiyunshan Hutchison Hutchison") was established in May 2005 as a joint venture between Guangzhou Pharmaceutical Group Baiyunshan Pharmaceutical Co., Ltd. and Hutchison Whampoa (China) Co., Ltd., a subsidiary of Mr. Li Ka-shing, a patriotic businessman. The joint venture, formerly known as Guangzhou Baiyunshan Traditional Chinese Medicine Factory, was established in May 1988 and was born from the farm operation area established in 1956, and transitioned to a tonic factory with both agriculture and industry, and then transformed into Guangzhou Baiyunshan Traditional Chinese Medicine Factory, which operates medicine and health business. The company has 1,212 employees, including 1 academician, 1 expert with special allowance from the State Council, 5 doctors, 74 masters, and engineering and technical personnel account for 38% of the total number of employees. In 2014, the company's sales scale exceeded 2.6 billion yuan, and it is the largest single Chinese medicine production enterprise in South China, a national high-tech enterprise, a national innovative pilot enterprise, and won the honors of national advanced grass-roots party organization, national May Day labor award, national model worker and so on.

Standing at the forefront of the times and the height of the industry, the company takes the cross policy of "education, love, science and technology, innovation and responsibility" as the guide, takes the mission of "modernization of traditional Chinese medicine, internationalization of traditional Chinese medicine, popularization of traditional Chinese medicine, and popularization of traditional Chinese medicine", takes economic benefits as the center, grasps management internally, expands the market externally, implements the three strategies of "talent, brand and technology", and forms five core competitive advantages of scientific and technological innovation, responsible marketing, cultural inheritance, talent engineering and advanced party building. Especially since 1999, the company has entered a period of rapid growth and achieved leapfrog development. From 1999 to 2013, the scale of the enterprise expanded by 30 times, and the four indicators of sales, payment collection, output value and profit maintained a growth rate of more than 30%. The company actively builds a pioneer enterprise of modern Chinese medicine and marches into the advantageous enterprise of the big health industry.

The company established the first enterprise in South China, the Institute of Modern Chinese Medicine, and hired academician Liu Changxiao, an expert in pharmacokinetics, as the president; He cooperated with Nobel Prize winner and "Father of Viagra" Murad to develop and research compound salvia tablets and other products, and cooperated with Academician Zhong Nanshan to build the State Key Laboratory of Respiratory Diseases. The company has academician expert enterprise workstation and postdoctoral research workstation. The company takes the Enterprise Modern Chinese Medicine Research Institute as the core, and strives to improve the construction of national, provincial and municipal scientific and technological innovation platforms through the integration of external superior scientific and technological resources, and vigorously strengthens the construction of core technology development and independent innovation capabilities. The company took the lead in setting up an "independent innovation fund" with a long-term incentive mechanism in the country, and allocated 30 million yuan for the first time; The first enterprise in South China was established as the Institute of Modern Chinese Medicine, and Academician Zhong Nanshan, former president of the Chinese Medical Association, and Ren Dequan, former deputy director of the State Food and Drug Administration, were hired as honorary presidents, and Academician Liu Changxiao, an expert in pharmacokinetics, was appointed as the president, and Deng Tietao, Academician Xiao Peigen, Academician Li Lianda, Academician Chen Keji, and Academician Yao Kaitai were appointed as consultants. Guangzhou Modern Chinese Medicine Key Engineering Technology Research and Development Center was established, and passed the provincial enterprise technology center certification; Together with Liu Changxiao and other five academicians, we launched China's first "Industry-University-Research Alliance". Hutchison Baiyunshan was awarded the title of "Excellent Unit for the 10th Anniversary of the Construction of the Modernization of Traditional Chinese Medicine Science and Technology Industrial Base" by the Ministry of Science and Technology of the People's Republic of China, and was recognized as an "Innovative Enterprise" and "Intellectual Property Advantage Enterprise" in Guangdong Province, and has a postdoctoral research station. The company has successively established the largest GAP medicinal material base in China, as well as the GAP base of andrographis, salvia, notoginseng, Xihuangcao and other medicinal materials, and is the first in the country to pass the national GAP base certification. The research on the antiviral mechanism of Baiyunshan Banlangen has become the first batch of international cooperation projects of traditional Chinese medicine of the Ministry of Science and Technology of the People's Republic of China, and Baiyunshan Banlangen Granules has become the first traditional Chinese medicine product funded by the National Institutes of Health (NIH), the world's largest health research institution. Baiyunshan Hutchison won the bid for the national "major new drug creation" science and technology project in four projects, becoming the pharmaceutical company in Guangdong Province that has won the most bids for this national major special project at the same time. Led by Academician Zhong Nanshan, the first Chinese medicine antiviral research center in China - Baiyunshan Hutchison Chinese Medicine Antiviral Research Center was established. The company cooperated with the Institute of Pharmaceutical Plant Medicine of the Chinese Academy of Medical Sciences to complete the world's first medicinal plant - Salvia miltiorrhizae, and the Baiyun Mountain Salvia miltiorrhiza tablets became the first genetic Chinese medicine.

The company has invested heavily to build the "Shennong Thatched Cottage" traditional Chinese medicine museum and the corporate culture with the spirit of Shennong as the core, so as to strengthen cultural health and let more people know, understand and accept traditional Chinese medicine. "Shennong Thatched Cottage" integrates knowledge and interest, concentrates on the history of medicine, culture and Chinese herbal medicine planting, and has received more than 800,000 tourists at home and abroad, becoming a model of traditional Chinese medicine culture dissemination appreciated by both the elegant and the vulgar, and was praised by Zhang Dejiang, then member of the Political Bureau of the Central Committee, Secretary of the Guangdong Provincial Party Committee, and now a member of the Standing Committee of the Political Bureau of the Central Committee and chairman of the National People's Congress, as "an important achievement in building a strong province of traditional Chinese medicine and a major cultural province, and its social impact is very far-reaching". The company established the first "Shennong Traditional Chinese Medicine Culture Research Institute"; The establishment of a municipal art troupe - Shennong Art Troupe; and Guangzhou University of Traditional Chinese Medicine to jointly build "Shennong College"; Establishment of Shennong Medical Doctor Club; Launched the "Personal Health Service Project" and "Health Service Festival" of Shennong Club; Hosted the first Shennong Traditional Chinese Medicine Development Forum. In May 2010, Dr. Xu Cheng, Director of the Confucius Institute in Indianapolis, signed a strategic cooperation agreement with Li Chuyuan, Dean of Baiyunshan and Huang Shennong Institutes, to formally form a strategic alliance for the dissemination of Chinese medicine culture, vigorously promote the culture of Chinese medicine, and let the concept of Chinese medicine health care benefit the public.